Septerna (NASDAQ:SEPN) Price Target Raised to $40.00 at HC Wainwright

Septerna (NASDAQ:SEPN) had its price objective raised by equities research analysts at HC Wainwright from $35.00 to $40.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 42.15% from the company’s current price.

SEPN has been the subject of several other research reports. Wells Fargo & Company raised Septerna from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $18.00 to $28.00 in a research note on Friday, November 14th. Wall Street Zen downgraded shares of Septerna from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 10th. Zacks Research raised shares of Septerna from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Truist Financial started coverage on Septerna in a report on Monday, December 15th. They issued a “buy” rating and a $34.00 price target for the company. Finally, Raymond James Financial assumed coverage on shares of Septerna in a research report on Friday, December 19th. They set a “strong-buy” rating and a $38.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $34.67.

Septerna Stock Performance

Septerna stock traded down $0.88 during mid-day trading on Monday, reaching $28.14. 356,636 shares of the company were exchanged, compared to its average volume of 307,304. The firm’s 50-day simple moving average is $26.95 and its two-hundred day simple moving average is $22.42. Septerna has a twelve month low of $4.66 and a twelve month high of $32.63. The firm has a market cap of $1.26 billion, a PE ratio of -18.61 and a beta of 3.43.

Insider Activity

In related news, COO Elizabeth Bhatt sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $28.97, for a total value of $115,880.00. Following the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $5,046,834.73. This trade represents a 2.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Septerna

A number of hedge funds have recently added to or reduced their stakes in the stock. Deutsche Bank AG increased its holdings in shares of Septerna by 5.3% in the 4th quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock worth $415,000 after acquiring an additional 744 shares during the period. Global Retirement Partners LLC acquired a new stake in shares of Septerna in the fourth quarter valued at approximately $35,000. Covestor Ltd raised its holdings in shares of Septerna by 55.8% during the third quarter. Covestor Ltd now owns 3,620 shares of the company’s stock valued at $68,000 after buying an additional 1,296 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Septerna by 15.0% during the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after buying an additional 1,315 shares during the period. Finally, PharVision Advisers LLC boosted its position in shares of Septerna by 17.5% during the third quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock worth $224,000 after buying an additional 1,780 shares during the period.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.